Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with systemic therapies constituting the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the a…